Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$614M |
| 2 |
Apple
AAPL
|
+$443M |
| 3 |
BLD
TopBuild
BLD
|
+$391M |
| 4 |
SPCX
SpaceX
SPCX
|
+$329M |
| 5 |
Penumbra
PEN
|
+$203M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.96B |
| 2 |
NVIDIA
NVDA
|
+$425M |
| 3 |
SNDK
Sandisk
SNDK
|
+$88M |
| 4 |
Southern Company
SO
|
+$80.6M |
| 5 |
PPL
PPL Corp
PPL
|
+$74.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.4% |
| 2 | Industrials | 13.64% |
| 3 | Consumer Discretionary | 9.5% |
| 4 | Healthcare | 7.9% |
| 5 | Financials | 5.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOW
1301
Bowhead Specialty Holdings
BOW
$1.1B
| $382K | ﹤0.01% |
12,751
-43,798
| -77% | -$1.14M |
|
1302
Nuvation Bio
NUVB
$2.43B
| $380K | ﹤0.01% |
66,907
-96,780
| -59% | -$473K |
|
1303
Verastem
VSTM
$624M
| $379K | ﹤0.01% |
99,236
-84,740
| -46% | -$410K |
|
1304
Vitesse Energy
VTS
$720M
| $378K | ﹤0.01% |
23,998
-8,910
| -27% | -$158K |
|
1305
Capital Bancorp
CBNK
$595M
| $375K | ﹤0.01% |
+10,669
| New | +$342K |
|
1306
Kosmos Energy
KOS
$1.76B
| $374K | ﹤0.01% |
177,261
-919,062
| -84% | -$2.56M |
|
1307
Ouster
OUST
$2.77B
| $374K | ﹤0.01% |
+5,976
| New | +$201K |
|
1308
Select Water Solutions
WTTR
$2.54B
| $370K | ﹤0.01% |
18,536
-232,568
| -93% | -$4.07M |
|
1309
Peoples Financial Services
PFIS
$702M
| $368K | ﹤0.01% |
+5,541
| New | +$328K |
|
1310
Emergent Biosolutions
EBS
$260M
| $368K | ﹤0.01% |
+43,882
| New | +$367K |
|
1311
Calumet Specialty Products
CLMT
$4.31B
| $366K | ﹤0.01% |
10,162
-87,259
| -90% | -$2.93M |
|
1312
First American
FAF
$7.33B
| $366K | ﹤0.01% |
+5,336
| New | +$356K |
|
1313
AerSale
ASLE
$265M
| $365K | ﹤0.01% |
+57,777
| New | +$378K |
|
1314
Theravance Biopharma
TBPH
$883M
| $365K | ﹤0.01% |
+21,473
| New | +$356K |
|
1315
Zentalis Pharmaceuticals
ZNTL
$363M
| $364K | ﹤0.01% |
+74,966
| New | +$299K |
|
1316
Red Violet
RDVT
$1.14B
| $361K | ﹤0.01% |
5,660
-1,719
| -23% | -$81.3K |
|
1317
Valley National Bancorp
VLY
$7.82B
| $360K | ﹤0.01% |
24,575
-512,553
| -95% | -$6.96M |
|
|
HVAC
1318
AdvisorShares HVAC and Industrials ETF
HVAC
$14M
| $360K | ﹤0.01% |
+8,492
| New | +$338K |
|
1319
Ingles Markets
IMKTA
$1.61B
| $359K | ﹤0.01% |
4,055
-9,949
| -71% | -$889K |
|
1320
Amerant Bancorp
AMTB
$1.12B
| $359K | ﹤0.01% |
14,054
-18,096
| -56% | -$421K |
|
1321
Orthofix Medical
OFIX
$408M
| $359K | ﹤0.01% |
39,228
+27,137
| +224% | +$299K |
|
1322
Immatics
IMTX
$1.22B
| $354K | ﹤0.01% |
34,937
-15,228
| -30% | -$161K |
|
1323
Utz Brands
UTZ
$1.24B
| $352K | ﹤0.01% |
+45,706
| New | +$341K |
|
1324
Adtran
ADTN
$633M
| $351K | ﹤0.01% |
25,241
-234,675
| -90% | -$3.66M |
|
1325
Capri Holdings
CPRI
$1.55B
| $346K | ﹤0.01% |
18,614
-233,931
| -93% | -$4.49M |
|
Similar funds
Michael Gelband's Q2 2026 Portfolio in Review
As of Q2 2026, Michael Gelband held 2,230 positions worth $15.5B, up 23% from $12.6B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Michael Gelband deployed $1.45B of net new capital in Q2 2026, opening 735 new positions and adding to 384 existing holdings. Its largest new stake was SpaceX: 1,938,935 shares worth $331M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Tesla, an estimated $1.96B trimmed.
- Michael Gelband's largest Q2 2026 buy was SpaceX: 1,938,935 shares worth $331M.
- Michael Gelband added most to Amazon in Q2 2026, an estimated $614M increase.
- Michael Gelband's biggest Q2 2026 reduction was Tesla, cutting an estimated $1.96B.
- Michael Gelband fully exited Southern Company in Q2 2026, selling an estimated $80.6M.
- Michael Gelband's ten largest holdings make up 31% of its $15.5B portfolio in Q2 2026.
- Michael Gelband opened 735 new positions and closed 720 in Q2 2026.
- Michael Gelband's portfolio value rose 23% quarter-over-quarter to $15.5B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.